1. Home
  2. FAMI vs LPCN Comparison

FAMI vs LPCN Comparison

Compare FAMI & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmmi Inc.

FAMI

Farmmi Inc.

HOLD

Current Price

$0.19

Market Cap

16.7M

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.36

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FAMI
LPCN
Founded
2015
1997
Country
China
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.7M
19.1M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
FAMI
LPCN
Price
$0.19
$2.36
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
863.7K
64.8K
Earning Date
08-04-2025
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$1.81
52 Week High
$2.12
$12.37

Technical Indicators

Market Signals
Indicator
FAMI
LPCN
Relative Strength Index (RSI) 25.30 44.16
Support Level $0.18 $2.16
Resistance Level $1.49 $2.46
Average True Range (ATR) 0.08 0.12
MACD -0.03 -0.00
Stochastic Oscillator 0.86 6.25

Price Performance

Historical Comparison
FAMI
LPCN

About FAMI Farmmi Inc.

Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe and the Middle East under the Forasen and Farmmi brands.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: